Epsilogen Acquires TigaTx to Forge Leading Cancer Antibody Company
Deal News | Apr 07, 2025 | Biogeneration Ventures (BGV)
Epsilogen, a leader in the development of immunoglobulin E (IgE) antibody therapeutics, announces the acquisition of TigaTx, a Boston-based biotechnology company focused on engineered immunoglobulin A (IgA) antibodies. The merger aims to establish the world's leading pan-isotype cancer antibody company by combining Epsilogen's IgE expertise with TigaTx's IgA capabilities. This strategic acquisition enhances Epsilogen's pipeline, which now includes the anti-Folate Receptor IgE antibody MOv18 IgE, currently undergoing a Phase Ib trial in platinum-resistant ovarian cancer, and EPS 401, an anti-EGFR IgA antibody, with IND-enabling studies in progress. The acquisition facilitates the combination of antibody isotypes into a single molecule, promising improved immune responses against cancers. With proprietary platforms like IgEG and bispecific IgEs and IgEGs, Epsilogen is well-positioned to pioneer new antibody therapeutics in oncology. Furthermore, Dr. Sonia Gulati of Global BioAccess Fund joins Epsilogen's board, bolstering the company's strategic oversight.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United States – TigaTx is based in Boston, Massachusetts, indicating its geographical relevance to the U.S. market.
- United Kingdom – Epsilogen is headquartered in London, highlighting the UK as a significant geographic location for the company.
Industry
- Biotechnology – The article discusses the merger of two biotechnology companies, Epsilogen and TigaTx, aimed at advancing cancer antibody therapeutics.
- Pharmaceuticals – The acquisition involves the development and clinical trials of antibody-based therapeutics for cancer treatment, a key segment of the pharmaceutical industry.
Financials
- Undisclosed – The financial terms of the acquisition between Epsilogen and TigaTx have not been disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Epsilogen Ltd | Acquirer | Company | A UK-based company leading in the development of IgE, IgA, and IgG-based cancer therapeutics. |
| TigaTx, Inc. | Target Company | Company | A Boston-based biotechnology firm specializing in engineered IgA antibodies for cancer treatment. |
| Biogeneration Ventures | Private Equity Firm | Company | An investor in Epsilogen, influencing strategic growth and expansion. |
| Global BioAccess Fund | Investor | Company | A fund with representation on Epsilogen's board through Dr. Sonia Gulati, supporting its strategic direction. |
| Dr. Sonia Gulati | Board Member | Person | A principal at the Global BioAccess Fund, joining Epsilogen's board to provide strategic guidance. |
| Tim Wilson | CEO | Person | CEO of Epsilogen, overseeing the company's strategic expansion through the acquisition. |
| Pete Finan | Non-Executive Chairman | Person | Chairman of Epsilogen and a General Partner at Epidarex Capital, supporting the acquisition's strategic objectives. |